Heat Biologics Inc
HTBX
Market Cap$61.07M
Close$
$2.70
13.5% upside
Current Fair Value
13.5% upsideUndervalued by 13.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $61.07 Million |
|---|---|
| Enterprise Value | $48.55 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.41 |
| Beta | 0.3 |
| Outstanding Shares | 25,593,948 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.69 |
|---|---|
| PEG | -16.35 |
| Price to Sales | - |
| Price to Book Ratio | 0.6 |
| Enterprise Value to Revenue | 58.82 |
| Enterprise Value to EBIT | -1.37 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Heat Biologics Inc
39 employees
CEO: Jeffrey Wolf Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The C...